Free Shipping for order over $49 within the U.S.

Breviscapine

BREVISCAPINE

WHAT IS BREVISCAPINE?

Breviscapine is a natural compound extracted from Erigeron Breviscapus (Vant.) Hand.-Mazz., which is a Chinese herbal medicine that has been in use for the treatment of paralysis, rheumatism, gastritis, toothache, and fever for more than 600 years. It has been found only in China, in the provinces of Guangxi, Guizhou, Hunan, Sichuan, Tibet, and Yunnan.

WHY BREVISCAPINE?

Breviscapine is a crude extract of several flavonoids of Erigeron breviscapus.

Our breviscapine contains more than 98% of scutellarin, which has been traditionally used in China as an activating blood circulation medicine to improve cerebral blood supply.

The use of breviscapine for the treatment of hypertension, cerebral embolism, and paralysis due to cerebrovascular accident dates back to the 1970s. Recent studies have suggested that breviscapine can be used to treat cerebral infarction and diabetic nephropathy.

ACTIVE COMPOUNDS IN BREVISCAPINE

FLAVONOID

Scutellarin

As the primary active ingredient in Breviscapine, scutellarin’s (4′,5,6,7-tetrahydroxyflavone-7-O-glucuronide) increases cerebral blood flow. Studies have shown that it raises permeability of blood-brain barrier, increases nutritional blood flow of myocardium, raises immune function of body macrophage cell and counteraction against blood and oxygen depletion induced by hypophyseal pituitrin and thrombocyte agglutination.

Apigenin
Apigenin is found to have protective effect of adult neurogenesis and for the treatment of neurological diseases, disorders and injuries, by stimulating the generation of neuronal cells in the adult brain.
In addition, Apigenin readily crosses the blood-brain barrier and has not demonstrated toxicity at high doses. It could thus prevent amyloid beta deposition and tau phosphorylation due to neuroinflammation, which can lead to Alzheimer's disease.

WHY FARLONG® LIFEFLOWER® BREVISCAPINI™:

Farlong® Lifeflower® Breviscapini™ is a patented pharmaceutical grade Breviscapine.

U.S. Patent No.:6084080; China Patent No.: ZL 2011 1 0277789.1; ZL 2009 1 0163211.6.

QUALITY CONTROL SEED-TO-SALE TRACEABILITY

GAP Cultivation

GMP Manufacturing

GSP Logistic & Warehousing

Third Party Laboratory

FDA Compliance

Quality & Safety Guarantee

SCIENTIFIC EVIDENCE

Human and animal clinical trials and toxicity studies of breviscapine have been completed to show the clinical results for the treatment of cerebral ischemia stroke, coronary heart disease or pectoris.

A study titled “Post-marketing Safety Surveillance of Breviscapine Powder-Injection: a Registry Study” by Zhong Wang from China Academy of Chinese Medial Sciences has started in September 2015 and is currently in progress with 20,000 subjects enrolled.

PUBLICATIONS

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378964/

https://www.ncbi.nlm.nih.gov/pubmed/16023316

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319248/

https://www.ncbi.nlm.nih.gov/pubmed/28343073

https://www.ncbi.nlm.nih.gov/pubmed/18284815

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711585

http://www.foxnews.com/health/2011/01/17/lifeflower-treatment-stroke.html

http://en.cnki.com.cn/Article_en/CJFDTOTAL-YYGZ200721003.htm

http://dict.cn/Breviscapinum%20has%20the%20pharmacological%20effects%20such%20as%20increasing%20the%20blood%20flux%2Cimproving%20the%20microcirculation%2Cdilating%20the%20blood%20vessel%2Cantithrombus%20and%20so%20on_2E

https://www.ncbi.nlm.nih.gov/pubmed/18284815

https://www.ncbi.nlm.nih.gov/pubmed/17878763

http://journal.frontiersin.org/article/10.3389/fphar.2017.00289/full

https://clinicaltrials.gov/ct2/show/NCT02559960